Hi Team,
We closed and oversubscribed our Seed! We’ll be updating our website and making a public announcement with more details soon. While we were busy raising this past month, we continued to bring on new customers and partners and advance our product.
Summary
Pilot with DNA vector manufacturer for the pharmaceutical and bio-based products industry in Italy.
Exploring a partnership with iGEM, the largest global synthetic biology competition, to help screen their participant's projects – this will help increase visibility and further establish our brand.
DHS proposal with industry partner, Kromek, for a target agnostic biological threat detection device – we're proposing to adapt our software platform to Kromek's hardware build out.
Presenting to NYC Dept of Health on how they could use our platform for environmental monitoring next week
KPIs
Sales
# ongoing: 6
# letter of interest / memorandum: 2
# pilot: 4
# contract: 3
# reengage: 11
Wins
Oversubscribed Seed
Regulatory momentum
Multiple sources at HHS confirmed revised guidelines will go live this summer.
U.S House Rep Eshoo and Melissa Hopkins at Johns Hopkins Center for Health Security are putting together a federal bill for HHS to regulate gene synthesis – we're submitting comments alongside the IGSC.
This Month
Aligning with our fundraise announcement, we’re making updates to the aclid.bio site to better showcase our brand and communicate what we’re building
This should help with visibility and hiring in the coming months
Optimizing real-time screening
The current real-time screening infrastructure is only cost-effective for customers with high volumes
Instead, we want to offer this capability to all of our customers because it makes our product stickier and opens the door to expand our offering across checkout (e.g., payments, manufacturability, and DNA design)